INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $245 | +580.6% | 13,227 | +302.5% | 0.00% | – |
| Q2 2023 | $36 | -77.6% | 3,286 | -72.6% | 0.00% | – |
| Q1 2023 | $161 | -24.1% | 12,006 | -29.8% | 0.00% | – |
| Q4 2022 | $212 | -99.9% | 17,106 | -0.1% | 0.00% | – |
| Q3 2022 | $239,000 | +1.7% | 17,119 | +0.5% | 0.00% | – |
| Q2 2022 | $235,000 | -25.6% | 17,035 | -12.3% | 0.00% | – |
| Q1 2022 | $316,000 | +13.3% | 19,430 | +13.4% | 0.00% | – |
| Q4 2021 | $279,000 | +9.4% | 17,137 | -0.3% | 0.00% | – |
| Q3 2021 | $255,000 | -46.5% | 17,182 | -28.1% | 0.00% | – |
| Q2 2021 | $477,000 | -12.8% | 23,909 | +0.9% | 0.00% | -100.0% |
| Q1 2021 | $547,000 | -6.5% | 23,700 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $585,000 | -53.9% | 23,700 | -22.7% | 0.00% | -50.0% |
| Q3 2020 | $1,270,000 | -13.5% | 30,643 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,468,000 | -20.5% | 30,643 | +4.5% | 0.00% | -33.3% |
| Q1 2020 | $1,847,000 | -47.3% | 29,336 | +3.8% | 0.00% | -25.0% |
| Q4 2019 | $3,502,000 | +71.1% | 28,257 | -8.4% | 0.00% | +33.3% |
| Q3 2019 | $2,047,000 | -10.7% | 30,850 | +7.1% | 0.00% | 0.0% |
| Q2 2019 | $2,292,000 | -21.6% | 28,800 | +10.1% | 0.00% | -25.0% |
| Q1 2019 | $2,925,000 | +29.0% | 26,150 | +16.2% | 0.00% | +33.3% |
| Q4 2018 | $2,268,000 | -26.7% | 22,500 | -8.2% | 0.00% | -25.0% |
| Q3 2018 | $3,096,000 | +51.2% | 24,500 | +0.4% | 0.00% | +33.3% |
| Q2 2018 | $2,047,000 | -17.4% | 24,400 | -39.5% | 0.00% | 0.0% |
| Q1 2018 | $2,479,000 | +5.3% | 40,300 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,354,000 | +0.6% | 40,300 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,339,000 | -52.1% | 40,300 | 0.0% | 0.00% | -50.0% |
| Q2 2017 | $4,879,000 | +21.5% | 40,300 | +13.5% | 0.01% | +20.0% |
| Q1 2017 | $4,015,000 | +4.1% | 35,501 | +0.0% | 0.01% | 0.0% |
| Q4 2016 | $3,857,000 | -34.0% | 35,500 | 0.0% | 0.01% | -37.5% |
| Q3 2016 | $5,843,000 | +5.0% | 35,500 | -9.0% | 0.01% | 0.0% |
| Q2 2016 | $5,565,000 | +17.1% | 39,000 | +5.4% | 0.01% | +14.3% |
| Q1 2016 | $4,753,000 | -14.9% | 37,000 | -1.1% | 0.01% | -22.2% |
| Q4 2015 | $5,586,000 | -8.0% | 37,400 | +2.2% | 0.01% | -10.0% |
| Q3 2015 | $6,070,000 | -4.2% | 36,600 | +39.4% | 0.01% | +11.1% |
| Q2 2015 | $6,337,000 | -32.4% | 26,255 | -7.6% | 0.01% | -35.7% |
| Q1 2014 | $9,374,000 | – | 28,425 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |